Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Angiodynamics (ANGO) EBITDA Margin (2016 - 2025)

Angiodynamics (ANGO) has disclosed EBITDA Margin for 16 consecutive years, with 7.71% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 752.0% year-over-year to 7.71%, compared with a TTM value of 10.59% through Nov 2025, up 7267.0%, and an annual FY2025 reading of 13.66%, up 4966.0% over the prior year.
  • EBITDA Margin was 7.71% for Q4 2025 at Angiodynamics, up from 14.07% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 44.52% in Q3 2023 and bottomed at 265.88% in Q1 2024.
  • Average EBITDA Margin over 5 years is 23.25%, with a median of 12.47% recorded in 2021.
  • The sharpest move saw EBITDA Margin plummeted -25482bps in 2024, then surged 25203bps in 2025.
  • Year by year, EBITDA Margin stood at 11.09% in 2021, then increased by 14bps to 9.5% in 2022, then tumbled by -75bps to 16.59% in 2023, then grew by 8bps to 15.23% in 2024, then skyrocketed by 49bps to 7.71% in 2025.
  • Business Quant data shows EBITDA Margin for ANGO at 7.71% in Q4 2025, 14.07% in Q3 2025, and 7.22% in Q2 2025.